EB2 Inhibitors
EB2 inhibitors are a class of chemical compounds that specifically target and modulate the activity of the End Binding protein 2 (EB2). EB2, along with other members of the End Binding protein family, is essential for the proper functioning of microtubules, which are a component of the cytoskeleton in eukaryotic cells. Microtubules play a pivotal role in various cellular processes, including maintaining cell shape, enabling cell motility, and separating chromosomes during cell division. The End Binding proteins, including EB2, are critical in ensuring the stability of microtubules and in regulating their dynamics.
The precise interaction of EB2 inhibitors with their target involves binding to specific sites on the EB2 protein, which in turn affects the protein's interaction with microtubules. As a result of this inhibition, the dynamics and stability of microtubules can be perturbed, leading to various cellular effects. Since microtubules are involved in several crucial cellular processes, compounds that can effectively modulate their dynamics, like the EB2 inhibitors, have become an area of interest in the field of cell biology. Investigating the exact mechanisms and outcomes of EB2 inhibition can provide valuable insights into cell physiology, microtubule dynamics, and the broader implications of modulating cytoskeletal components.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is a reversible EGFR tyrosine kinase inhibitor that binds to the ATP-binding site of EGFR, preventing receptor phosphorylation and interfering with downstream signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a reversible EGFR inhibitor that competes with ATP for binding to EGFR's tyrosine kinase domain, disrupting EGFR phosphorylation and downstream signaling in cancer cells. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $114.00 $198.00 | 13 | |
Afatinib is an irreversible EGFR inhibitor that forms covalent bonds with EGFR, HER2, and HER4, inhibiting receptor phosphorylation and downstream signaling, which hinders cancer cell growth. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib is a third-generation EGFR inhibitor designed to target specific EGFR mutations, including T790M. It binds irreversibly to EGFR, inhibiting its activity and impeding cancer cell proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual EGFR and HER2 inhibitor that blocks the tyrosine kinase activity of both receptors. | ||||||
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $92.00 $214.00 $383.00 $755.00 $1250.00 | 4 | |
Neratinib is an irreversible EGFR/HER2 inhibitor that forms covalent bonds with these receptors, leading to sustained inhibition of signaling pathways involved in cell growth. | ||||||
Pelitinib | 257933-82-7 | sc-208155 | 5 mg | $430.00 | ||
Pelitinib is a reversible EGFR inhibitor that competes with ATP for binding to EGFR's tyrosine kinase domain. It inhibits EGFR phosphorylation, disrupting downstream signaling pathways. | ||||||
AZD8931 | 848942-61-0 | sc-364426 sc-364426A | 5 mg 10 mg | $260.00 $490.00 | ||
Sapitinib, also known as AZD8931, is an irreversible EGFR inhibitor that forms a covalent bond with EGFR. It inhibits EGFR phosphorylation and downstream signaling, impeding cancer cell growth. | ||||||